Y-mAbs Announces Regulatory Filing for DANYELZA® (naxitamab-gqgk) in Brazil
Y-mAbs Therapeutics, Inc. (“Y-mAbs”, NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel,
New York United States Globe Newswirey Mabs Therapeutics Inc Us Federal Drug Administration Brazilian Health Regulatory Agency Y Mabs Therapeutics Inc
Source: einnews.com